Clinical Trial

Evaluation of Juläine (TM) for the Treatment of Atrophic Facial Acne Scars

Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the effectiveness and safety of Juläine, an injectable medical device made of polylactic acid, for treating facial acne scars. Participants with atrophic acne scars will be randomly assigned to receive either Juläine or a placebo (saline). The treatment will consist of three injection sessions over two months, followed by a 12-month observation period. The study will measure changes in scar severity and skin quality over time using clinical assessments and imaging tools. The study is being conducted at multiple dermatology clinics in Poland and is approved by a local ethics committee.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-07-01; most recent amendment 2026-03-16.
Status change: Not Yet Recruiting → Recruiting 2026-03-13
Trial Details
NCT Number NCT07058883
Lead Sponsor Nordberg Medical AB
Conditions Acne Scars
Enrollment 55 participants
Start Date 2026-03-13
Primary Completion 2026-12 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-18